From investor concall…loss of revenue estimate of Rs.150 Cr and failure to supply penalties of Rs.21 Cr …these are kind of one off …
R&D Exp of Rs.43 Cr in Q1FY24…expected to go upwards of Rs.50 Cr in subsequent quarters of FY24
Gradual improvement expected in Margin from Q2 onwards but management declined to confirm any guidance around revenue & margin for rest of FY24…
They also discontinued giving molecule wise sales break-up because of competition
| Subscribe To Our Free Newsletter |
